Literature DB >> 11554165

Significant correlations of E-cadherin, catenin, and CD44 variant form expression with carcinoma cell differentiation and prognosis of extrahepatic bile duct carcinomas.

T Mikami1, M Saegusa, H Mitomi, N Yanagisawa, M Ichinoe, I Okayasu.   

Abstract

To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas. 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays. Levels of E-cadherin, alpha-catenin, and beta-catenin proteins were lower in carcinomas than in normal mucosa, while CD44 variants 3 and 6 were upregulated. Well-differentiated carcinoma showed higher expression of E-cadherin and alpha-catenin than moderately to poorly differentiated types. Macroscopically papillary lesions had higher expression of E-cadherin than their nonpapillary counterparts. RT-PCR/SBH for CD44 revealed the CD44 variant form to be more prevalent in carcinoma than in normal mucosa, correlating with the immunohistochemical results, and with more exon variety. The Cox proportional hazards test identified histologic type and E-cadherin expression as prognostic factors. Among the examined molecules, E-cadherin was especially related to papillary mass formation and a good prognosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11554165     DOI: 10.1309/VV6D-3GAH-VEJM-DUJT

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells.

Authors:  Pongsanat Pongcharoen; Artit Jinawath; Rutaiwan Tohtong
Journal:  Clin Exp Metastasis       Date:  2011-08-11       Impact factor: 5.150

Review 2.  Recent advances in the regulation of cholangiocyte proliferation and function during extrahepatic cholestasis.

Authors:  Shannon S Glaser; Paolo Onori; Candace Wise; Fuguan Yang; Marco Marzioni; Domenico Alvaro; Antonio Franchitto; Romina Mancinelli; Gianfranco Alpini; Md Kamruzzaman Munshi; Eugenio Gaudio
Journal:  Dig Liver Dis       Date:  2010-02-13       Impact factor: 4.088

3.  Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer.

Authors:  Jian-Wei Xie; Peng-Chen Chen; Chao-Hui Zheng; Ping Li; Jia-Bin Wang; Jian-Xian Lin; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Yao Lin; Chang-Ming Huang
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-26       Impact factor: 4.553

Review 4.  Cholangiocyte proliferation and liver fibrosis.

Authors:  Shannon S Glaser; Eugenio Gaudio; Tim Miller; Domenico Alvaro; Gianfranco Alpini
Journal:  Expert Rev Mol Med       Date:  2009-02-25       Impact factor: 5.600

Review 5.  Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis.

Authors:  Jacqueline M Benjamin; W James Nelson
Journal:  Semin Cancer Biol       Date:  2007-09-04       Impact factor: 15.707

6.  A pituitary gene encodes a protein that produces differentiation of breast and prostate cancer cells.

Authors:  Micsunica Platica; Elena Ivan; James F Holland; Alin Ionescu; Sheryl Chen; John Mandeli; Pamela D Unger; Ovidiu Platica
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

7.  Regulation of CD44v6 expression in gastric carcinoma by the IL-6/STAT3 signaling pathway and its clinical significance.

Authors:  Yuan-Yuan Xu; Ming Guo; Liu-Qing Yang; Fan Zhou; Cao Yu; Aixiu Wang; Tao-Hong Pang; Hong-Yan Wu; Xiao-Ping Zou; Wei-Jie Zhang; Lei Wang; Gui-Fang Xu; Qin Huang
Journal:  Oncotarget       Date:  2017-07-11

8.  The prognostic significance of E-cadherin expression in laryngeal squamous-cell carcinoma: a systematic review.

Authors:  M Re; F M Gioacchini; A Scarpa; C Cassandro; M Tulli; E Cassandro
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-11-09       Impact factor: 2.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.